C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease

Johannes Landskron, Sigrid M. Kraggerud, Elisabeth Wik, Anne Dørum, Merete Bjørnslett, Espen Melum, Øystein Helland, Line Bjørge, Ragnhild A. Lothe, Helga B. Salvesen, Kjetil Taskén

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The pan lymphocyte marker CD45 exists in various isoforms arising from alternative splicing of the exons 4, 5 and 6. While naïve T cells express CD45RA translated from an mRNA containing exon 4, exons 4–6 are spliced out to encode the shorter CD45R0 in antigen-experienced effector/memory T cells. The SNP C77G (rs17612648) is located in exon 4 and blocks the exon’s differential splicing from the pre-mRNA, enforcing expression of CD45RA. Several studies have linked C77G to autoimmune diseases but lack of validation in other cohorts has left its role elusive. An incidental finding in an ovarian cancer patient cohort from West Norway (Bergen region, n = 312), suggested that the frequency of C77G was higher among ovarian cancer patients than in healthy Norwegians (n = 1,357) (3.0% vs. 1.8% allele frequency). However, this finding could not be validated in a larger patient cohort from South-East Norway (Oslo region, n = 1,198) with 1.2% allele frequency. Hence, C77G is not associated with ovarian cancer in the Norwegian population. However, its frequency was increased in patients with FIGO stage II, endometrioid histology or an age at diagnosis of 60 years or older indicating a possible association with a less aggressive cancer type.

Original languageEnglish (US)
Article numbere0182030
JournalPloS one
Volume12
Issue number7
DOIs
StatePublished - Jul 2017

Fingerprint

ovarian neoplasms
Ovarian Neoplasms
exons
Exons
Alleles
alleles
T-cells
Norway
Gene Frequency
gene frequency
T-lymphocytes
CD45 Antigens
T-Lymphocytes
Histology
Incidental Findings
Lymphocytes
autoimmune diseases
RNA Precursors
alternative splicing
Alternative Splicing

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease. / Landskron, Johannes; Kraggerud, Sigrid M.; Wik, Elisabeth; Dørum, Anne; Bjørnslett, Merete; Melum, Espen; Helland, Øystein; Bjørge, Line; Lothe, Ragnhild A.; Salvesen, Helga B.; Taskén, Kjetil.

In: PloS one, Vol. 12, No. 7, e0182030, 07.2017.

Research output: Contribution to journalArticle

Landskron, J, Kraggerud, SM, Wik, E, Dørum, A, Bjørnslett, M, Melum, E, Helland, Ø, Bjørge, L, Lothe, RA, Salvesen, HB & Taskén, K 2017, 'C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease', PloS one, vol. 12, no. 7, e0182030. https://doi.org/10.1371/journal.pone.0182030
Landskron, Johannes ; Kraggerud, Sigrid M. ; Wik, Elisabeth ; Dørum, Anne ; Bjørnslett, Merete ; Melum, Espen ; Helland, Øystein ; Bjørge, Line ; Lothe, Ragnhild A. ; Salvesen, Helga B. ; Taskén, Kjetil. / C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease. In: PloS one. 2017 ; Vol. 12, No. 7.
@article{c6ea5ab7b3ed434c86a24dd3a592ebe5,
title = "C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease",
abstract = "The pan lymphocyte marker CD45 exists in various isoforms arising from alternative splicing of the exons 4, 5 and 6. While na{\"i}ve T cells express CD45RA translated from an mRNA containing exon 4, exons 4–6 are spliced out to encode the shorter CD45R0 in antigen-experienced effector/memory T cells. The SNP C77G (rs17612648) is located in exon 4 and blocks the exon’s differential splicing from the pre-mRNA, enforcing expression of CD45RA. Several studies have linked C77G to autoimmune diseases but lack of validation in other cohorts has left its role elusive. An incidental finding in an ovarian cancer patient cohort from West Norway (Bergen region, n = 312), suggested that the frequency of C77G was higher among ovarian cancer patients than in healthy Norwegians (n = 1,357) (3.0{\%} vs. 1.8{\%} allele frequency). However, this finding could not be validated in a larger patient cohort from South-East Norway (Oslo region, n = 1,198) with 1.2{\%} allele frequency. Hence, C77G is not associated with ovarian cancer in the Norwegian population. However, its frequency was increased in patients with FIGO stage II, endometrioid histology or an age at diagnosis of 60 years or older indicating a possible association with a less aggressive cancer type.",
author = "Johannes Landskron and Kraggerud, {Sigrid M.} and Elisabeth Wik and Anne D{\o}rum and Merete Bj{\o}rnslett and Espen Melum and {\O}ystein Helland and Line Bj{\o}rge and Lothe, {Ragnhild A.} and Salvesen, {Helga B.} and Kjetil Task{\'e}n",
year = "2017",
month = "7",
doi = "10.1371/journal.pone.0182030",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease

AU - Landskron, Johannes

AU - Kraggerud, Sigrid M.

AU - Wik, Elisabeth

AU - Dørum, Anne

AU - Bjørnslett, Merete

AU - Melum, Espen

AU - Helland, Øystein

AU - Bjørge, Line

AU - Lothe, Ragnhild A.

AU - Salvesen, Helga B.

AU - Taskén, Kjetil

PY - 2017/7

Y1 - 2017/7

N2 - The pan lymphocyte marker CD45 exists in various isoforms arising from alternative splicing of the exons 4, 5 and 6. While naïve T cells express CD45RA translated from an mRNA containing exon 4, exons 4–6 are spliced out to encode the shorter CD45R0 in antigen-experienced effector/memory T cells. The SNP C77G (rs17612648) is located in exon 4 and blocks the exon’s differential splicing from the pre-mRNA, enforcing expression of CD45RA. Several studies have linked C77G to autoimmune diseases but lack of validation in other cohorts has left its role elusive. An incidental finding in an ovarian cancer patient cohort from West Norway (Bergen region, n = 312), suggested that the frequency of C77G was higher among ovarian cancer patients than in healthy Norwegians (n = 1,357) (3.0% vs. 1.8% allele frequency). However, this finding could not be validated in a larger patient cohort from South-East Norway (Oslo region, n = 1,198) with 1.2% allele frequency. Hence, C77G is not associated with ovarian cancer in the Norwegian population. However, its frequency was increased in patients with FIGO stage II, endometrioid histology or an age at diagnosis of 60 years or older indicating a possible association with a less aggressive cancer type.

AB - The pan lymphocyte marker CD45 exists in various isoforms arising from alternative splicing of the exons 4, 5 and 6. While naïve T cells express CD45RA translated from an mRNA containing exon 4, exons 4–6 are spliced out to encode the shorter CD45R0 in antigen-experienced effector/memory T cells. The SNP C77G (rs17612648) is located in exon 4 and blocks the exon’s differential splicing from the pre-mRNA, enforcing expression of CD45RA. Several studies have linked C77G to autoimmune diseases but lack of validation in other cohorts has left its role elusive. An incidental finding in an ovarian cancer patient cohort from West Norway (Bergen region, n = 312), suggested that the frequency of C77G was higher among ovarian cancer patients than in healthy Norwegians (n = 1,357) (3.0% vs. 1.8% allele frequency). However, this finding could not be validated in a larger patient cohort from South-East Norway (Oslo region, n = 1,198) with 1.2% allele frequency. Hence, C77G is not associated with ovarian cancer in the Norwegian population. However, its frequency was increased in patients with FIGO stage II, endometrioid histology or an age at diagnosis of 60 years or older indicating a possible association with a less aggressive cancer type.

UR - http://www.scopus.com/inward/record.url?scp=85026418037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026418037&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0182030

DO - 10.1371/journal.pone.0182030

M3 - Article

C2 - 28759630

AN - SCOPUS:85026418037

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0182030

ER -